How well do patients with a first episode of schizophrenia respond to antipsychotics: A systematic review and meta-analysis

European Neuropsychopharmacology

Volumn 27, Issue 9, 2017, Pages 835-844

  Zhu, Yikang ^a,b   Li, Chunbo ^b   Huhn, Maximilian ^a   Rothe, Philipp ^c   Krause, Marc ^a   Bighelli, Irene ^a   Schneider Thoma, Johannes ^a   Leucht, Stefan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c Department of Psychiatry and Psychotherapy   (Germany)

Author keywords

Antipsychotics; First episode schizophrenia; Response

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; ZUCLOPENTHIXOL;

BIOSIS; BRIEF PSYCHIATRIC RATING SCALE; COCHRANE LIBRARY; EMBASE; HUMAN; MEDLINE; MENTAL PATIENT; META ANALYSIS; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCINFO; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SCORING SYSTEM; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; ACUTE DISEASE;

ACUTE DISEASE; ANTIPSYCHOTIC AGENTS; HUMANS; SCHIZOPHRENIA;

EID: 85021347922     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2017.06.011     Document Type: Review

References (62)

1. Adams, C., Coutinho, E., Davis, J.M., Duggan, L., Essali, A., Fenton, M., Cochrane Schizophrenia Group. The Cochrane Library. 2011, Wiley & Sons Ltd., Chichester, UK.
2. Agid, O., Kapur, S., Arenovich, T., Zipursky, R.B., Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch. Gen. Psychiatry 60 (2003), 1228–1235.
3. Agid, O., Siu, C.O., Potkin, S.G., Kapur, S., Watsky, E., Vanderburg, D., Zipursky, R.B., Remington, G., Meta-regression analysis of placebo response in antipsychotic trials, 1970–2010. Am. J. Psychiatry 170 (2013), 1335–1344.
4. Amr, M., Lakhan, S.E., Sanhan, S., Al-Rhaddad, D., Hassan, M., Thiabh, M., Shams, T., Efficacy and tolerability of quetiapine versus haloperidol in first-episode schizophrenia: a randomized clinical trial. Int. Arch. Med, 6, 2013, 47.
5. Angermeyer, M.C., Goldstein, J.M., Kuehn, L., Gender differences in schizophrenia: rehospitalization and community survival. Psychol. Med 19 (1989), 365–382.
6. Borenstein, M., Hedges, L.V., Higgins, J.P.T., Rothstein, H.R., Introduction to Meta-analysis. 2009, John Wiley & Sons, Ltd., Chichester.
7. Buchanan, R.W., Carpenter, W.T., Kaplan & Sadock׳s Comprehensive Textbook of Psychiatry, 8th ed., 2005, Lippincott Williams & Wilkins, Philadelphia, PA.
8. Chaudhuri, B.P., Bhagabati, D., Medhi, D., Risperidone versus haloperidol in acute and transient psychotic disorder. Indian J. Psychiatry 42 (2000), 280–290.
9. Cole, J.O., Phenothiazine treatment in acute schizophrenia. Arch. Gen. Psychiatry 10 (1964), 246–261.
10. Crespo-Facorro, B., Perez-Iglesias, R., Ramirez-Bonilla, M., Martinez-Garcia, O., Llorca, J., Luis Vazquez-Barquero, J., A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. J. Clin. Psychiatry 67 (2006), 1511–1521.
11. Crossley, N.A., Constante, M., McGuire, P., Power, P., Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br. J. Psychiatry 196 (2010), 434–439.
12. DALYs, G.B.D., Collaborators, H., Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388 (2016), 1603–1658.
13. Elbourne, D.R., Altman, D.G., Higgins, J.P., Curtin, F., Worthington, H.V., Vail, A., Meta-analyses involving cross-over trials: methodological issues. Int. J. Epidemiol. 31 (2002), 140–149.
14. Emsley, R., Oosthuizen, P., Koen, L., Niehaus, D., Martinez, L., Comparison of treatment response in second-episode versus first-episode schizophrenia. J. Clin. Psychopharmacol. 33 (2013), 80–83.
15. Emsley, R.A., Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone working group. Schizophr. Bull. 25 (1999), 721–729.
16. Fagerlund, B., Mackeprang, T., Gade, A., Glenthoj, B.Y., Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first-episode drug-naive schizophrenic patients. CNS Spectr. 9 (2004), 364–374.
17. Furukawa, T.A., Cipriani, A., Barbui, C., Brambilla, P., Watanabe, N., Imputing response rates from means and standard deviations in meta-analyses. Int. Clin. Psychopharmacol. 20 (2005), 49–52.
18. Furukawa, T.A., Levine, S.Z., Tanaka, S., Goldberg, Y., Samara, M., Davis, J.M., Cipriani, A., Leucht, S., Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies. JAMA Psychiatry 72 (2015), 14–21.
19. Gaebel, W., Janner, M., Frommann, N., Pietzcker, A., Kopcke, W., Linden, M., Muller, P., Muller-Spahn, F., Tegeler, J., First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophr. Res. 53 (2002), 145–159.
20. Gardner, D.M., Murphy, A.L., O׳Donnell, H., Centorrino, F., Baldessarini, R.J., International consensus study of antipsychotic dosing. Am. J. Psychiatry 167 (2010), 686–693.
21. Guy, W., ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare Public Health Service Alcohol. 1976, Drug Abuse, and Mental Health Administration, Rockville, MD.
22. Higgins, J.P., Green, S., Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. 2011, John Wiley & Sons, Chichester.
23. Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560.
24. Jaaskelainen, E., Juola, P., Hirvonen, N., McGrath, J.J., Saha, S., Isohanni, M., Veijola, J., Miettunen, J., A systematic review and meta-analysis of recovery in schizophrenia. Schizophr. Bull. 39 (2013), 1296–1306.
25. Kahn, R.S., Fleischhacker, W.W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I.P., Gheorghe, M.D., Rybakowski, J.K., Galderisi, S., Libiger, J., Hummer, M., Dollfus, S., Lopez-Ibor, J.J., Hranov, L.G., Gaebel, W., Peuskens, J., Lindefors, N., Riecher-Rossler, A., Grobbee, D.E., group, Es, Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371 (2008), 1085–1097.
26. Lee, S.M., Chou, Y.H., Li, M.H., Wan, F.J., Yen, M.H., Effects of haloperidol and risperidone on cerebrohemodynamics in drug-naive schizophrenic patients. J. Psychiatr. Res. 42 (2008), 328–335.
27. Leucht, S., Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application. J. Clin. Psychiatry 75 (2014), 8–14.
28. Leucht, S., Busch, R., Hamann, J., Kissling, W., Kane, J.M., Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol. Psychiatry 57 (2005), 1543–1549.
29. Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Orey, D., Richter, F., Samara, M., Barbui, C., Engel, R.R., Geddes, J.R., Kissling, W., Stapf, M.P., Lassig, B., Salanti, G., Davis, J.M., Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382 (2013), 951–962.
30. Leucht, S., Davis, J.M., Engel, R.R., Kane, J.M., Wagenpfeil, S., Defining ׳response׳ in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology 32 (2007), 1903–1910.
31. Leucht, S., Kane, J.M., Kissling, W., Hamann, J., Etschel, E., Engel, R., Clinical implications of Brief Psychiatric Rating Scale scores. Br. J. Psychiatry 187 (2005), 366–371.
32. Leucht, S., Kane, J.M., Kissling, W., Hamann, J., Etschel, E., Engel, R.R., What does the PANSS mean?. Schizophr. Res. 79 (2005), 231–238.
33. Leucht, S., Leucht, C., Huhn, M., Chaimani, A., Mavridis, D., Helfer, B., Samara, M., Tardy, M., Cipriani, A., Geddes, J.R., Salanti, G., Davis, J.M., 60 years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis and meta-regression of efficacy predictors. Am. J. Psychiatry, 2017 appiajp201716121358.
34. Leucht, S., Samara, M., Heres, S., Davis, J.M., Dose equivalents for antipsychotic drugs: the DDD method. Schizophr. Bull. 42:Suppl 1 (2016), S90–S94.
35. Leucht, S., Samara, M., Heres, S., Patel, M.X., Furukawa, T., Cipriani, A., Geddes, J., Davis, J.M., Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method. Schizophr. Bull. 41 (2015), 1397–1402.
36. Leucht, S., Samara, M., Heres, S., Patel, M.X., Woods, S.W., Davis, J.M., Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr. Bull. 40 (2014), 314–326.
37. Levine, S.Z., Rabinowitz, J., Engel, R., Etschel, E., Leucht, S., Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophr. Res. 98 (2008), 318–322.
38. Li, T., Wang, Q., Zhang, J., Rolls, E.T., Yang, W., Palaniyappan, L., Zhang, L., Cheng, W., Yao, Y., Liu, Z., Gong, X., Luo, Q., Tang, Y., Crow, T.J., Broome, M.R., Xu, K., Li, C., Wang, J., Liu, Z., Lu, G., Wang, F., Feng, J., Brain-wide analysis of functional connectivity in first-episode and chronic stages of schizophrenia. Schizophr. Bull, 43, 2017, 436-448.
39. Lieberman, J.A., Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J. Clin. Psychiatry 57 (1996), 68–71.
40. Lieberman, J.A., Koreen, A.R., Chakos, M., Sheitman, B., Woerner, M., Alvir, J.M., Bilder, R., Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J. Clin. Psychiatry 57:Suppl 9 (1996), S5–S9.
41. Lieberman, J.A., Phillips, M., Gu, H., Stroup, S., Zhang, P., Kong, L., Ji, Z., Koch, G., Hamer, R.M., Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 28 (2003), 995–1003.
42. Lieberman, J.A., Tollefson, G., Tohen, M., Green, A.I., Gur, R.E., Kahn, R., McEvoy, J., Perkins, D., Sharma, T., Zipursky, R., Wei, H., Hamer, R.M., Group, H.S., Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am. J Psychiatry 160 (2003), 1396–1404.
43. McCleery, A., Ventura, J., Kern, R.S., Subotnik, K.L., Gretchen-Doorly, D., Green, M.F., Hellemann, G.S., Nuechterlein, K.H., Cognitive functioning in first-episode schizophrenia: MATRICS consensus cognitive battery (MCCB) Profile of Impairment. Schizophr. Res. 157 (2014), 33–39.
44. McEvoy, J.P., Lieberman, J.A., Perkins, D.O., Hamer, R.M., Gu, H., Lazarus, A., Sweitzer, D., Olexy, C., Weiden, P., Strakowski, S.D., Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am. J. Psychiatry 164 (2007), 1050–1060.
45. McMahon, R.P., Kelly, D.L., Boggs, D.L., Li, L., Hu, Q.Y., Davis, J.M., Carpenter, W.T., Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research. Schizophr. Bull. 34 (2008), 292–301.
46. Moller, H.J., Riedel, M., Jager, M., Wickelmaier, F., Maier, W., Kuhn, K.U., Buchkremer, G., Heuser, I., Klosterkotter, J., Gastpar, M., Braus, D.F., Schlosser, R., Schneider, F., Ohmann, C., Riesbeck, M., Gaebel, W., Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. Int. J. Neuropsychopharmacol. 11 (2008), 985–997.
47. Obermeier, M., Mayr, A., Schennach-Wolff, R., Seemuller, F., Moller, H.J., Riedel, M., Should the PANSS be rescaled?. Schizophr. Bull. 36 (2010), 455–460.
48. Obermeier, M., Schennach-Wolff, R., Meyer, S., Moller, H.J., Riedel, M., Krause, D., Seemuller, F., Is the PANSS used correctly? A systematic review. BMC Psychiatry, 11, 2011, 113.
49. Ohlsen, R.I., O׳Toole, M.S., Purvis, R.G., Walters, J.T., Taylor, T.M., Jones, H.M., Pilowsky, L.S., Clinical effectiveness in first-episode patients. Eur. Neuropsychopharmacol. 14:Suppl 4 (2004), S445–S451.
50. Rabinowitz, J., Werbeloff, N., Caers, I., Mandel, F.S., Stauffer, V., Menard, F., Kinon, B.J., Kapur, S., Determinants of antipsychotic response in schizophrenia: implications for practice and future clinical trials. J. Clin. Psychiatry 75 (2014), e308–e316.
51. Samara, M.T., Spineli, L.M., Furukawa, T.A., Engel, R.R., Davis, J.M., Salanti, G., Leucht, S., Imputation of response rates from means and standard deviations in schizophrenia. Schizophr. Res. 151 (2013), 209–214.
52. San, L., Arranz, B., Perez, V., Safont, G., Corripio, I., Ramirez, N., Duenas, R., Alvarez, E., One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis. Psychiatry Res. 200 (2012), 693–701.
53. Sanger, T.M., Lieberman, J.A., Tohen, M., Grundy, S., Beasley, C. Jr., Tollefson, G.D., Olanzapine versus haloperidol treatment in first-episode psychosis. Am. J. Psychiatry 156 (1999), 79–87.
54. Sanz-Fuentenebro, J., Taboada, D., Palomo, T., Aragues, M., Ovejero, S., Del Alamo, C., Molina, V., Randomized trial of clozapine vs. risperidone in treatment-naive first-episode schizophrenia: results after one year. Schizophr. Res. 149 (2013), 156–161.
55. Schennach-Wolff, R., Obermeier, M., Seemuller, F., Jager, M., Schmauss, M., Laux, G., Pfeiffer, H., Naber, D., Schmidt, L.G., Gaebel, W., Klosterkotter, J., Heuser, I., Maier, W., Lemke, M.R., Ruther, E., Klingberg, S., Gastpar, M., Engel, R.R., Moller, H.J., Riedel, M., Does clinical judgment of baseline severity and changes in psychopathology depend on the patient population? Results of a CGI and PANSS linking analysis in a naturalistic study. J. Clin. Psychopharmacol. 30 (2010), 726–731.
56. Schooler, N., Rabinowitz, J., Davidson, M., Emsley, R., Harvey, P.D., Kopala, L., McGorry, P.D., Van Hove, I., Eerdekens, M., Swyzen, W., De Smedt, G., Early Psychosis Global Working, G., Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am. J. Psychiatry 162 (2005), 947–953.
57. Sham, P.C., Maclean, C.J., Kendler, K.S., A typological model of schizophrenia based on age at onset, sex and familial morbidity. Acta Psychiatr. Scand. 89 (1994), 135–141.
58. Sikich, L., Frazier, J.A., McClellan, J., Findling, R.L., Vitiello, B., Ritz, L., Ambler, D., Puglia, M., Maloney, A.E., Michael, E., De Jong, S., Slifka, K., Noyes, N., Hlastala, S., Pierson, L., McNamara, N.K., Delporto-Bedoya, D., Anderson, R., Hamer, R.M., Lieberman, J.A., Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am. J. Psychiatry 165 (2008), 1420–1431.
59. Svestka, J., Synek, O., Zourkova, A., Olanzapine versus risperidone in first-episode schizophrenic and schizoform disorders: a double-blind comparison. Eur. Neuropsychopharmacol., 13, 2003, S291.
60. Torres, U.S., Duran, F.L., Schaufelberger, M.S., Crippa, J.A., Louza, M.R., Sallet, P.C., Kanegusuku, C.Y., Elkis, H., Gattaz, W.F., Bassitt, D.P., Zuardi, A.W., Hallak, J.E., Leite, C.C., Castro, C.C., Santos, A.C., Murray, R.M., Busatto, G.F., Patterns of regional gray matter loss at different stages of schizophrenia: a multisite, cross-sectional VBM study in first-episode and chronic illness. NeuroImage Clin. 12 (2016), 1–15.
61. Woodhead, M., 80% of China׳s clinical trial data are fraudulent, investigation finds. BMJ, 355, 2016, i5396.
62. Zhang, J.P., Gallego, J.A., Robinson, D.G., Malhotra, A.K., Kane, J.M., Correll, C.U., Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int. J. Neuropsychopharmacol. 16 (2013), 1205–1218.